BioWorld Asia

March 27, 2002

View Archived Issues

Amrad’s Stock Falls On Poor Phase II Results For Emfilermin

New Gene Inhibition Technique Aims To Hasten Gene Analysis

Schering To Purchase Collateral For $140M In Stock Exchange

Millennium, Compugen In Deal For Protein Pathway Software

Cyclacel, University Of Edinburgh Form Drug Design Collaboration

Avidex Platform Creates TCRs; Company Planning Partnerships

U.S. Research Foundation Backs Swedish Stem Cell Program

ReGen’s Phase IIa Interim Data Not Significant In Alzheimer’s

Other News To Note

Vernalis Seeks Second Nasdaq Listing, Reports Profitability

J&J Buying Tibotec-Virco For $320 In Cash And Debt

PARIS Johnson & Johnson signed a definitive agreement to acquire all of the assets of Tibotec-Virco NV for $320 million in cash and debt. (BioWorld International) Read More

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

Illustration of red and white blood cells in an artery

Case report links APOLD1 variant to vascular-type bleeding disorder

BioWorld Science

Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...